HER 2 LOW-EXPRESSING BREAST CANCER
Clinical trials for HER 2 LOW-EXPRESSING BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER 2 LOW-EXPRESSING BREAST CANCER trials appear
Sign up with your email to follow new studies for HER 2 LOW-EXPRESSING BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can switching between two powerful drugs beat breast cancer longer?
Disease control Not yet recruitingThis study tests whether alternating two targeted drugs (sacituzumab govitecan and trastuzumab deruxtecan) can help people with a specific type of advanced breast cancer (HER2-low triple-negative) live longer compared to using just one drug alone. About 260 adults with metastatic…
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New study aims to improve how we measure drug response in breast cancer
Knowledge-focused Not yet recruitingThis study looks at whether a special type of PET scan can better detect if the drug trastuzumab deruxtecan (T-DXd) is working in people with HER2 low breast cancer that has spread. The goal is to identify non-responders earlier than standard CT scans, so they can avoid unnecessa…
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: NA • Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated Jun 17, 2026 07:11 UTC